---
title: "HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294401035.md"
description: "Schall, Brown & Schwartz LLP is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. The probe examines whether the company issued misleading statements or failed to disclose material information, particularly regarding an FTC lawsuit alleging privacy breaches and deceptive billing practices. Investors who suffered losses are encouraged to contact the firm to discuss their rights."
datetime: "2026-07-30T18:08:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294401035.md)
  - [en](https://longbridge.com/en/news/294401035.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294401035.md)
---

# HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law

**HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law**

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“ Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws.

**INVESTIGATION DETAILS:** The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Hims & Hers is the subject of an FTC lawsuit filed on July 29, 2026. According to the FTC, the Company “shared consumers’ sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers’ privacy and deceives users about its billing and cancellation practices.”

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.com

**WHY SBS?** Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP  
Brian Schall, Esq.,  
Andrew Brown, Esq.,  
David Schwartz, Esq.,  
www.schallfirm.com  
Office: 310-301-3335  
info@schallfirm.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260730332686/en/

### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md)
- [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md)
- [HIYY.US](https://longbridge.com/en/quote/HIYY.US.md)

## Related News & Research

- [HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder](https://longbridge.com/en/news/293791898.md)
- [Is Today's Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock?](https://longbridge.com/en/news/293781114.md)
- [FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight](https://longbridge.com/en/news/293756607.md)
- [BUZZ-Hims gains after FDA panel votes to place popularly used peptide BPC-157 on compounding list](https://longbridge.com/en/news/293649384.md)
- [ANALYSIS-Hims & Hers stands to gain if the FDA loosens restrictions on peptides](https://longbridge.com/en/news/293593520.md)